podcasts

High-throughput screening: rapid advancements in drug discovery

Posted: 29 February 2024 | | No comments yet

Listen to this podcast where we explore the latest technological advancements in high throughput screening and more.

In this episode titled: High throughput screening: rapid advancements in drug discovery, we explore the latest technological advancements in the field and more.

This conversation features Dr Luke Alderwick, Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL), and Dr Sachin Mahale, Research Leader in High Throughput Screening at Charles River Laboratories.

Key learning points: 

  • What are the key technological advancements driving the efficacy and accuracy of High Throughput Screening (HTS) methods?
  • How does HTS contribute to the identification of potential off-target effects and toxicity of drug candidates?
  • How does the integration of omics approaches into HTS methodologies enhance the depth of understanding of biological systems?

This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.

About our speakers

bioDr Luke Alderwick

Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL).

With over 15 years experience in (High Throughput Screening) HTS and assay development across multiple therapeutic areas and assay modalities. Luke has recently transitioned from academic Professor to industry Scientist and Group Leader, and as such working for a CRO in Early Drug Discovery, Luke has employed his unique skill-set and experience in HTS / HitID projects to enable CRL drug discovery partners to accelerate their drug discovery endeavors.

Sachin MahaleDr Sachin Mahale

Research Leader in High Throughput Screening at Charles River Laboratories.

Sachin G. Mahale, PhD is the Research Leader at Charles River Laboratories and overseeing number of novel drug discovery programs ranging from hit identification to hit to lead campaigns.

He received his M.Sc. in Advanced Biological Sciences from University of Pune, India. Sachin was awarded a PhD fellowship at Leicester University from CRUK to identify novel small molecule inhibitors of Cdk4 for the treatment of cancer. His postdoctoral research included novel target identification for neurodegenerative conditions and acted as Principle investigator on several research grants from Welsh Assembly Government (WAG).

Prior to joining Charles River Sachin was Principal Scientist/Senior Project Leader at RedX Pharma and focused his research in the field of immune-oncology and he ran several drug discovery programs which lead to identifying clinical candidates.